Real-world Evidence of Systemic Treatment Practices for Biliary Tract Cancer in Japan: Results of a Database Study

Overview

Journal J Hepatobiliary Pancreat Sci

Date 2024 Jul 2

PMID 38953871

Authors

Makoto Ueno

Sachiyo Shirakawa

Jumpei Tokumaru

Mizue Ogi

Kenichiro Nishida

Takehiro Hirai

Kenta Shinozaki

Yoko Hamada

Hiroshi Kitagawa

Akihiko Horiguchi

Affiliations

Soon will be listed here.

Abstract

Purpose: To describe the real-world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan.

Methods: Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look-back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection-induced treatment interruption were analyzed.

Results: The full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first-line regimens were S-1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011-September 2021). Patients who received monotherapies tended to be older. Biliary infection-induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0-145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0-92.0) days.

Conclusions: These results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first-line treatment, and the management of biliary infections during systemic therapy.

Citing Articles

Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study.

Ueno M, Shirakawa S, Tokumaru J, Ogi M, Nishida K, Hirai T J Hepatobiliary Pancreat Sci. 2024; 31(7):468-480.

PMID: 38953871 PMC: 11503459. DOI: 10.1002/jhbp.1418.

References

Makiuchi T, Sobue T . Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan. Eur J Cancer Prev. 2022; 32(1):2-9. DOI: 10.1097/CEJ.0000000000000758. View

Satoh T, Sakata Y . S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother. 2012; 13(13):1943-59. DOI: 10.1517/14656566.2012.709234. View

Kimura-Seto K, Kojima Y, Komori S, Hisada Y, Otake Y, Yanai Y . Main causes of death in advanced biliary tract cancer. Cancer Med. 2023; 12(9):10889-10898. PMC: 10225207. DOI: 10.1002/cam4.5794. View

Turjeman A, von Dach E, Molina J, Franceschini E, Koppel F, Yelin D . Duration of antibiotic treatment for Gram-negative bacteremia - Systematic review and individual participant data (IPD) meta-analysis. EClinicalMedicine. 2022; 55:101750. PMC: 9722443. DOI: 10.1016/j.eclinm.2022.101750. View

Fruscione M, Pickens R, Baker E, Martinie J, Iannitti D, Hwang J . Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review. Curr Probl Cancer. 2020; 45(1):100614. DOI: 10.1016/j.currproblcancer.2020.100614. View

Ahn D, Reardon J, Ahn C, Bupathi M, Mikhail S, Wu C . Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. Int J Cancer. 2017; 142(8):1671-1675. DOI: 10.1002/ijc.31144. View

Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T . Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023; 401(10372):195-203. DOI: 10.1016/S0140-6736(22)02038-4. View

Morizane C, Ueno M, Ikeda M, Okusaka T, Ishii H, Furuse J . New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol. 2018; 48(8):703-711. DOI: 10.1093/jjco/hyy082. View

Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H . Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2022; 30(1):102-110. PMC: 10086809. DOI: 10.1002/jhbp.1219. View

10.

Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S . Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2005; 57(5):647-53. DOI: 10.1007/s00280-005-0095-3. View

11.

Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G . NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2020; 15(7):1147-1159. DOI: 10.1016/j.jtho.2020.03.002. View

12.

Fujinaga J, Fukuoka T . A Review of Research Studies Using Data from the Administrative Claims Databases in Japan. Drugs Real World Outcomes. 2022; 9(4):543-550. PMC: 9712845. DOI: 10.1007/s40801-022-00331-5. View

13.

Ueno M, Shirakawa S, Tokumaru J, Ogi M, Nishida K, Hirai T . Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study. J Hepatobiliary Pancreat Sci. 2024; 31(7):468-480. PMC: 11503459. DOI: 10.1002/jhbp.1418. View

14.

Laurent T, Simeone J, Kuwatsuru R, Hirano T, Graham S, Wakabayashi R . Context and Considerations for Use of Two Japanese Real-World Databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs Real World Outcomes. 2022; 9(2):175-187. PMC: 8932467. DOI: 10.1007/s40801-022-00296-5. View

15.

Oh D, He A, Qin S, Chen L, Okusaka T, Vogel A . Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2024; 1(8):EVIDoa2200015. DOI: 10.1056/EVIDoa2200015. View

16.

Jiang S, Geng S, Chen Q, Zhang C, Cheng M, Yu Y . Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients. Front Oncol. 2022; 12:823705. PMC: 8864310. DOI: 10.3389/fonc.2022.823705. View

17.

Kelley R, Ueno M, Yoo C, Finn R, Furuse J, Ren Z . Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10391):1853-1865. DOI: 10.1016/S0140-6736(23)00727-4. View

18.

Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M . Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019; 30(12):1950-1958. DOI: 10.1093/annonc/mdz402. View

19.

Jung C, Lavole J, Barret M, Ali E, Palmieri L, Dermine S . Local Therapy in Advanced Cholangiocarcinoma: A Review of Current Endoscopic, Medical, and Oncologic Treatment Options. Oncology. 2019; 97(4):191-201. DOI: 10.1159/000500832. View

20.

Tagashira Y, Sakamoto N, Isogai T, Hikone M, Kosaka A, Chino R . Impact of inadequate initial antimicrobial therapy on mortality in patients with bacteraemic cholangitis: a retrospective cohort study. Clin Microbiol Infect. 2017; 23(10):740-747. DOI: 10.1016/j.cmi.2017.02.027. View